Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-77.2% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | $3.81 -1.04% -1.05% 170K

Professional, Scientific, and T...

(0.0% 1d) (-23.8% 1m) (-47.9% 1y) (0.0% 2d) (0.0% 3d) (-5.2% 7d) (-44.49% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 187,226,185
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

BIOXYTRAN, INC

BIXT A | $0.1285 490.75% 32K

Professional, Scientific, and T...

(0.0% 1d) (16.6% 1m) (-73.5% 1y) (0.0% 2d) (8.3% 3d) (-10.8% 7d) (813.76% volume)
Earnings Calendar:
Market Cap: $ 22,356,691
https://www.bioxytraninc.com/
Sec Filling | Patents | 3 employees

(US) bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.

injection

add to watch list Paper trade email alert is off

Monte Rosa Therapeutics Inc

GLUE | $5.84 -1.35% -1.37% 110K

Professional, Scientific, and T...

(0.0% 1d) (-22.9% 1m) (2.3% 1y) (0.0% 2d) (0.9% 3d) (-11.0% 7d) (5.5% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 292,876,000
https://www.monterosatx.com
Sec Filling | Patents | 60 employees

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.

drug discovery profitable computational machine learning

add to watch list Paper trade email alert is off

ImmunoPrecise Antibodies Ltd

IPA | $1.24 0.0% 150K

Professional, Scientific, and T...

(0.0% 1d) (-10.0% 1m) (-59.1% 1y) (0.0% 2d) (-0.8% 3d) (1.6% 7d) (155.05% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 32,630,922
http://www.immunoprecise.com/
Sec Filling | Patents | 2021 employees

(CA) IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.

covid antibody

add to watch list Paper trade email alert is off

IonQ Inc

IONQ 4 | $7.09 -3.8% -0.42% 4.8M

Professional, Scientific, and T...

(0.0% 1d) (-24.7% 1m) (13.4% 1y) (0.0% 2d) (-2.6% 3d) (-5.8% 7d) (20.77% volume)
Earnings Calendar:
Market Cap: $ 1,476,347,290
https://ionq.com
Sec Filling | Patents | n/a employees

IonQ, Inc. is a leader in quantum computing, with a proven track record of innovation and deployment. IonQ’s next-generation quantum computer is the world’s most powerful trapped-ion quantum computer, and IonQ has defined what it believes is the best path forward to scale. IonQ is the only company with its quantum systems available through the cloud on Amazon Braket, Microsoft Azure, and Google Cloud, as well as through direct API access. IonQ was founded in 2015 by Christopher Monroe and Jungsang Kim based on 25 years of pioneering research.

computational

add to watch list Paper trade email alert is off

Lyell Immunopharma Inc

LYEL | $2.24 -3.86% -4.02% 1.1M

Professional, Scientific, and T...

(0.0% 1d) (9.3% 1m) (-3.5% 1y) (0.0% 2d) (-6.3% 3d) (-7.1% 7d) (4.71% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 569,175,737
https://lyell.com
Sec Filling | Patents | 189 employees

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

genetic t-cell renewable

add to watch list Paper trade email alert is off

Panbela Therapeutics Inc

PBLA | $0.4895 -6.31% 66K

Professional, Scientific, and T...

(0.0% 1d) (-34.4% 1m) (-97.0% 1y) (0.0% 2d) (-19.2% 3d) (-22.2% 7d) (363.69% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,376,454
http://www.sunbiopharma.com/
Sec Filling | Patents | 6 employees

(US) Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

cancer treatment pancreatic

add to watch list Paper trade email alert is off

Pyxis Oncology Inc

PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

(0.0% 1d) (-16.1% 1m) (25.7% 1y) (0.0% 2d) (-13.9% 3d) (-12.2% 7d) (14.2% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 241,544,173
https://pyxisoncology.com
Sec Filling | Patents | 2021 employees

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

cancer t-cell

add to watch list Paper trade email alert is off